title: Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.
abstract: BACKGROUND
  The purpose of this study was to evaluate the feasibility and compliance of adjuvant chemotherapy of S-1 plus carboplatin for patients with completely resected non-small cell lung cancer (NSCLC) of pathological stage IB-IIIB.
  
  
  METHODS
  S-1 was given orally at a dose of 80 mg/m²/day for 2 weeks, followed by a 2-week period of no treatment. Carboplatin was given intravenously on day 8 at an area under the curve of 6. This regimen was repeated for four to six 28-day courses.
  
  
  RESULTS
  Seventeen patients were enrolled in this study. Fourteen of them completed at least 4 cycles of chemotherapy. Nine patients had grade 2 and three patients had grade 3 thrombocytopenia, respectively. Severe nonhematologic toxicities were uncommon. Treatment was delayed in a few patients because of prolonged thrombocytopenia.
  
  
  CONCLUSIONS
  We concluded that the regimen was feasible and tolerable for patients with completely resected NSCLC as adjuvant chemotherapy.
authors.affiliation: Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan.
authors.forename: Yoshitoshi
authors.initials: Y
authors.lastname: Komazaki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sakashita
authors.forename: Masashi
authors.initials: M
authors.lastname: Furuiye
authors.forename: Toshihide
authors.initials: T
authors.lastname: Fujie
authors.forename: Meiyo
authors.initials: M
authors.lastname: Tamaoka
authors.forename: Yuki
authors.initials: Y
authors.lastname: Sumi
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Katsuo
authors.initials: K
authors.lastname: Kojima
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Jin
authors.forename: Naohiko
authors.initials: N
authors.lastname: Inase
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D012372:ROC Curve; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D016190:Carboplatin